Clinical Trial Update: Study Using WST11 in Patients With Localized Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study using WST11 (padoporfin) for localized prostate cancer has completed; the update does not include reported results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Padoporfin (WST11) (padoporfin)

Snippet

Sponsor: Steba Biotech S.A. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED